Neuren Media and Analyst Coverage, page-877

Apologies if posted already. Interesting that they have recently sold NEU. I've not yet had a chance to research how much they may have been holding:

Merchant Group’s Andrew Chapman names his top four biotech stocks | The Australian

Recent biotech winnersRight then, the juicy bits you’ve probably been waiting for in this piece – biotech stock success stories to date for the fund, and its top picks looking ahead. Some, have already actually been mentioned.Starting with recent excellent performers, Chapman said the ones driving the fund’s success over the past few months include: Arovella Therapeutics (ASX:ALA), PharmAust (ASXAA), Neurotech (ASX:NTI), and Neuren Pharmaceuticals (ASX:NEU).“These ones are have all been long-term holds, so they aren’t new additions, but they’ve all been winners of late,” he said, noting that the firm did sell out of NEU recently.As for stocks that Chapman believes are primed for a rally in favourable conditions this year, he has four…